Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)

12/01/2021 | 05:30pm EST

Item 7.01. Regulation FD Disclosure.

On December 1, 2021, Enochian BioSciences Inc., a Delaware corporation (the "Company") made available a corporate presentation at the World Vaccine & Immunotherapy Congress (the "Corporate Presentation"). The Corporate Presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The Company undertakes no duty or obligation to update or revise information included in this Report or the Exhibit.

© Edgar Online, source Glimpses

All news about ENOCHIAN BIOSCIENCES, INC.
2021ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)
AQ
2021Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on P..
AQ
2021ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure (form 8-K)
AQ
2021ENOCHIAN BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition a..
AQ
2021Enochian Biosciences, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
2021Amendment to Annual Report (Form 10-K/A)
PU
2021Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
2021ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
2021ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
2021Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -9,71x
Yield 2021 -
Capitalization 260 M 260 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,9%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.-31.69%260
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805